Kempharm Enterprise Value over EBITDA Trend from 2010 to 2021

KMPH -  USA Stock  

USD 10.75  0.24  2.18%

Kempharm Enterprise Value over EBITDA is decreasing over the last several years with slightly volatile swings. Enterprise Value over EBITDA is predicted to flatten to -15.13. During the period from 2010 to 2021 Kempharm Enterprise Value over EBITDA regressed destribution of quarterly values had coefficient of variationof(63.95) and r-value of (0.57). Kempharm Selling General and Administrative Expense is most likely to increase significantly in the upcoming years. The last year's value of Selling General and Administrative Expense was reported at 7.92 Million. The current Weighted Average Shares is estimated to increase to about 4.3 M, while Consolidated Income is projected to decrease to (13.8 M).

Search Historical Trends 

 
Refresh
Check Kempharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kempharm main balance sheet or income statement drivers, such as Gross Profit of 14.6 M, Interest Expense of 4.7 M or Operating Expenses of 26.1 M, as well as many exotic indicators such as Asset Turnover of 1.26, Current Ratio of 1.14 or Gross Margin of 0.89. Kempharm financial statements analysis is a perfect complement when working with Kempharm Valuation or Volatility modules. It can also supplement various Kempharm Technical models. Please see the analysis of Kempharm Correlation against competitors.

Kempharm Enterprise Value over EBITDA Breakdown

Showing smoothed Enterprise Value over EBITDA of Kempharm with missing and latest data points interpolated. Measures the ratio between [EV] and [EBITDAUSD].Kempharm's Enterprise Value over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kempharm's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value over EBITDA10 Years Trend
Decreasing
Slightly volatile
 Enterprise Value over EBITDA 
Share
      Timeline 

Kempharm Enterprise Value over EBITDA Regression Statistics

Arithmetic Mean(6.67)
Geometric Mean 5.75
Coefficient Of Variation(63.95)
Mean Deviation 3.37
Median(4.82)
Standard Deviation 4.26
Sample Variance 18.18
Range 12.46
R-Value(0.57)
Mean Square Error 13.58
R-Squared 0.32
Significance 0.05
Slope(0.67)
Total Sum of Squares 199.94

Kempharm Enterprise Value over EBITDA History

2016 (10.34) 
2017 (3.83) 
2018 (2.66) 
2019 (4.40) 
2020 (14.74) 
2021 (15.13) 

About Kempharm Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Kempharm income statement, its balance sheet, and the statement of cash flows. Kempharm investors use historical funamental indicators, such as Kempharm's Enterprise Value over EBITDA, to determine how well the company is positioned to perform in the future. Although Kempharm investors may use each financial statement separately, they are all related. The changes in Kempharm's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kempharm's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Kempharm Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Kempharm. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Enterprise Value over EBITDA(14.74) (15.13) 
Enterprise Value114 M118.9 M
Tangible Asset Value11.2 M11.5 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-7.7 M-8.3 M
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.

Kempharm Investors Sentiment

The influence of Kempharm's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kempharm. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - KMPH

Kempharm Investor Sentiment

Most of Macroaxis users are now bullish on Kempharm. What is your trading attitude regarding investing in Kempharm? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kempharm using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Kempharm Correlation against competitors. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.